

Studies on Haemostatic Parameters of Type 2 Diabetics in Owerri, Imo State

Edward Ukamaka C^{1*}, Nwanjo Harrison U¹, Nwosu Dennis C¹, and Obeagu Emmanuel Ifeanyi^{1,2}

¹Department of Medical Laboratory Science, Imo State University, Owerri, Nigeria

²Medical Laboratory Science, University Health Services, Michael Okpara University, Umudike, Abia State, Nigeria

DOI: [10.36348/SJMPS.2019.v05i10.004](https://doi.org/10.36348/SJMPS.2019.v05i10.004)

| Received: 02.10.2019 | Accepted: 09.10.2019 | Published: 11.10.2019

*Corresponding author: Edward Ukamaka C

Abstract

Type 2 diabetes mellitus is a chronic metabolic disorder which has emerged as a health challenge globally due to its insidious onset, late recognition and complications. The present study was aimed at evaluation of haemostatic parameters in Owerri. Cross Sectional Studies was conducted at Federal Medical Center and Imo State specialist Hospital, Owerri. A total of three hundred subjects which include each one hundred and fifty type 2 diabetics and apparently control subjects between the ages forty and sixty nine years were recruited. Ten millimeters of venous blood as aseptically collected from the subjects. Platelet count and coagulation assay were used for determination of these parameters. The data was analyzed using statistical package for social science 20.0. Test with a probability value of $P < 0.05$ was considered statistically significant. Results from haemostatic parameters showed higher statistically significant value ($P = 0.001$) in platelet count (226.68 ± 19.40 vs $205.86 \pm 13.33 \times 10^9/l$), and fibrinogen (370.19 ± 21.55 v $2.63.56 \pm 32.31$ mg/dl) when type 2 diabetics was compared with control subjects. Inversely, there was statistically significantly lower values; ($P = 0.031$) in prothrombin time (13.47 ± 0.96 v 14.06 ± 0.96 s) and ($P = 0.001$) in activated partial thromboplastin time (34.39 ± 2.17 v 37.25 ± 1.82). There was statistically significant progressive increase in activated partial thromboplastin time (33.56 ± 1.56 , 34.44 ± 2.32 , 36.60 ± 1.80 s) and ($P = 0.001$) fibrinogen (362.22 ± 21.72 , 369.82 ± 22.65 , 378.54 ± 17.69 mg/dl). Also higher significant value in female compared with male (380.21 ± 16.62 v 360.17 ± 21.35). The increase found in acute proteins, malondialdehyde, platelet count, fibrinogen and decrease in antioxidants, prothrombin time and APTT showed that type 2 diabetics is a state of chronic low grade inflammation, increased oxidative stress and hypercoagulable state which may result in increase morbidity and premature mortality of type 2 diabetes.

Keywords: Haemostatic parameters, type 2 diabetics, Owerri.

Copyright @ 2019: This is an open-access article distributed under the terms of the Creative Commons Attribution license which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use (NonCommercial, or CC-BY-NC) provided the original author and source are credited.

INTRODUCTION

Diabetes Mellitus is a chronic metabolic disease which is associated with a high incidence rate of morbidity and mortality globally. Type 2 diabetes mellitus is the most prevalent one and makes up 90% of cases of diagnosed diabetes [1]. Type 2 diabetes mellitus formerly known as non-insulin dependent diabetes mellitus or adult-onset diabetes is a metabolic disorder that is characterized by hyperglycaemia due to insulin resistance and relative reduced insulin secretion by beta pancreatic cells [2]. International Diabetic Federation [3] reported that 425 million (8.8%) adults between the ages of twenty to seventy - nine years had diabetes and predicted to rise up to 625 (9.9%) by the year 2045. According to Adeloje *et al.*, [4], the pooled prevalence of type 2 diabetes in Nigeria in 2017 was 5.7%. Also, the prevalence of 5.7% was reported by

Uloko *et al.*, [5] as pooled geopolitical prevalence in 2018. In Imo State, the prevalence of type 2 diabetes was 8.7% which was reported among geriatric individuals [6].

Haemostasis is the process that maintains the integrity of circulating system after vascular damage [7]. Under normal circumstance, vessel wall injury rapidly initiates series of co-ordinate events designed to seal the breach generated by the injury. This leads to platelets recruitment and activation, blood coagulation; extrinsic and intrinsic way as well as generation of thrombin and fibrin [8]. Circulatory disturbances in diabetes are characterized by alteration in platelet activity, coagulopathy, fibrinolytic aberration, haemorrhagic factors and changes in endothelial metabolism [9]. Diabetes leads to hypercoagulable state which encompasses abnormalities

such as thrombocytosis or antithrombin iii deficiencies and vascular endothelial cells are exposed to high glucose levels leading to elevation of tissue - type plasminogen activator in the plasma accompanied by impaired fibrinolysis [10].

The study aimed to evaluate the levels of acute phase inflammatory proteins, oxidative stress markers and haemostatic parameters in Type 2 Diabetics.

MATERIAL AND METHODS

Study Area

The cross sectional study was conducted at Federal Medical Centre, Owerri and Imo State Specialist Hospital, Owerri.

Study Population

The sample size for the study was calculated using the formula below, according to Aronye [11]. The prevalence rate of type 2 diabetes mellitus in Imo State is 8.7% [6].

$$n = z^2 p(q)/d^2$$

Where

$$q = 1 - P$$

$$n = \text{Sample size}$$

$$p = \text{prevalence of type 2 of diabetes mellitus in Imo State- 8.7\%}$$

$$z = \text{confidence interval 95\% - 1.96}$$

$$d = \text{Degree of accuracy- 0.05}$$

$$n = 1.96^2 \times 0.087(1-0.087)/0.05^2 = 3.8416 \times 0.07943/0.0025$$

$$= 122.057 = 122$$

Therefore, the minimum sample size will be 122.

Subjects

Three hundred subjects of both sex between the ages of fifty to sixty-nine years were recruited for the study. One hundred and fifty type 2 diabetics attending clinic of Federal Medical Centre, Owerri and Imo State Specialist Hospital, Owerri for at least six months were eligible for the study. Also, one hundred and fifty apparently healthy individuals were recruited who came for check up for medical fitness and served as the control subjects.

They were further grouped according to their ages 40-49, 50-59 and 60-69 years, and also according to sex; male (n=75) and female (n=75)

Parameters Studied

The parameters evaluated in this study include platelet count, prothrombin time, activated partial thromboplastin time and fibrinogen.

Study Design

This is a cross-sectional study that involved type 2 diabetics and control subjects.

Site of the Study

The analysis was carried out at the Haematology laboratory of the Department of Medical Laboratory Science of Imo State University, Owerri and Federal Medical Center, Owerri through a letter obtained from the Head of Department through my Supervisor.

Laboratory Procedure

All reagents were commercially purchased and the manufacturer's standard operating procedures were strictly adhered to.

Determination of Glucose

This was carried out by enzymatic oxidase - peroxidase method according to Tietz *et al.*, [12] as modified by Randox Laboratories, United Kingdom. Catalog number; GL 1021, GL 304, GL366.

Procedure

Three dry cleaned plain test tubes were setup in a rack, labeled test, standard and blank. Then, 20µl of sample and standard were pipetted into the tubes labeled test and standard respectively. In all the tubes, 2000µl of reagents I was added. The tubes were gently mixed, incubated at 37°C for 10 minutes. The absorbance of sample and standard were read spectrophotometrically at 500nm.

Determination of Platelet Count

This was carried out by direct current detecting method, according to Lewis *et al.*, [13] using Sysmex Automated Haematology Analyzer KX- 2IN Model.

Procedure

The sequenstrene blood sample was placed in the spiral mixer and allowed to mix well. The whole blood was activated in the LCD screen; the sample number (code) was input by pressing enter. The sample was mixed well. The cap was removed and the sample inserted into the probe and the stand switch was pressed. The LCD screen displayed the analysis. The sample was removed and re-capped. The unit executed the analysis automatically and the result was displayed on the screen.

Determination of Prothrombin Time

The test was carried out by one stage prothrombin time according to Lewis *et al.*, [13] as modified by Agappe Diagnostic Switzerland. Catalogue Number; 5261003, 52601004

Procedure

A clear dry test tube was set up in a rack. The reagent vial was swirled gently before use. The

prothrombin reagent was dispensed from the vial and it was pre-warmed of 37°C for 10 minutes. 100 µl of plasma was added to pre-warmed curvette and was incubated at 37°C for 3 minutes. 200 µl pre-warmed prothrombin reagent was added to test curvette containing the pre-warmed sample. The time was started and the clotting time was recorded.

Determination of Activated Partial Thromboplastin Time

This was carried out by manual coagulation method according to Lewis *et al.*, [13].

Procedure

The reagent vials were gently mixed to a homogenized suspension and swirled before use. Enough volume of reagent 1 Calcium chloride reagent 2 (APTT reagent) were pre-warmed at 37°C for ten minutes prior to use. A test curvette was set up at 37°C in a water bath, 100µl of plasma was pipette into it, followed by an addition 100µ of pre-warmed APTT reagent 2 well mixed and incubated for three minutes forcibly, 100 µ of pre-warmed reagent 1 (calcium chloride) was added into it... a timer was started simultaneously and the clotting time was read recorded in formation of clot in seconds.

Determination of Fibrinogen

This was carried out by semi-automated coagulation method according to Clauss, 1957. As modified by Giessie Diagonstic, Italy. Catalogue number: 1004, 1005, 1006, 1007.

Procedure

A semi-automated Rayto 220c colgulotmeter was used. In a clean dry tube, 25µl of plasma was pipette into it and 225µl of imidazole buffer was added to make 1: 10 dilution. A test curvette was added into the holder and there was a display prompted to add sample displayed on the screen. Then 100µl of diluted sample was pipette into the test curvette and it was incubated for five minutes and a display showed sample warming. There was another display in the screen prompted to add reagent, 50µl of thrombin was added with a display showing on the screen testing. The result was displayed on the screen and was recorded.

STATISTICAL ANALYSIS

Data was analyzed using software, statistical package for social science (SPSS), version 20.0. The results were expressed as mean and standard deviation (mean±SD). Comparison of differences in the mean values between the groups were assessed using one way analysis of variance (Anova) and Independent student T – test. Variable between the age groups was assessed using Post Hoc test.

RESULTS

Table-1: Comparison of the Mean Values of Haemostatic Parameters in Type 2 Diabetes Mellitus and Control Subjects of the Study Population

| Parameters | Type 2 diabetes mellitus subjects (n = 150) mean ± SD | Control subjects (n = 150) mean± SD | T-test | P-value |
|---|---|-------------------------------------|--------|---------|
| Platelet count (10 ⁹ /L) | 226.68± 19.40* | 205.86± 13.33 | 10.833 | 0.0001 |
| Prothrombin time (S) | 13.47 ±1.25* | 14.06 ±0.79 | 7.920 | 0.031 |
| Activated partial thromboplastin time (S) | 34.39 ±2.17* | 37.25 ±2.10 | 11.402 | 0.001 |
| Fibrinogen (mg/dl) | 370.19 ±21.55* | 263.58±32.31 | 33.616 | 0.0001 |

KEY

n: Number of subjects in each group
•: statistically significant when compared with type 2 diabetic group (P<0.05).

Table-1 shows the mean values of haemostatic parameter; platelet count and prothrombin time, activated partial thromboplastin time and fibrinogen in type 2 diabetics and control subjects. Result from this study, showed that the mean value of platelet count (226.68 ± 19.40) was higher in type 2 diabetics and was statistically significant (P = 0.0001) when compared with the mean value (205.86 ± 13.33) of the control subjects.

The mean value of prothrombin time (13.47 ± 1.25) was lower in type 2 diabetics which was statistically significant (P=0.031) when compared with the control subjects (14.06 ± 0.96).

Result showed that the mean value of activated partial thromboplastin time (34.39±2.17) was lower in type 2 diabetics which was statistically significant (P=0.001) when compared with the mean value (37.25±1.82) of the control subjects.

Inversely, the mean value of fibrinogen (370.19±24.55) was higher in type 2 diabetics which was statistically significant (P=0.001) when compared with the mean value (263.58 ± 32.31) of the control subjects.

Table-2: The Mean Values of Haemostatic Parameters in Type 2 Diabetes Mellitus Subjects in Relation to Age of the Study Population

| Parameters | 40-49 Years (n=50) mean \pm SD | 50-59 Years (n=50) Mean \pm SD | 60-69 (n = 50) mean \pm SD | F-value | P-value | P-value a vs b | P-value b vs c |
|---|-------------------------------------|-------------------------------------|---------------------------------|---------|---------|----------------|----------------|
| Platelet count ($\times 10^9$ Cells/L) | 231.44 \pm 18.44 | 226.18 \pm 21.58 | 222.42 \pm 17.23 | 2.792 | 0.065 | 0.358 | 0.590 |
| Prothrombin time (Seconds) | 13.60 \pm 1.31 | 13.52 \pm 1.20 | 13.28 \pm 1.23 | 0.892 | 0.412 | 0.945 | 0.602 |
| APTT (Seconds) | 33.56 \pm 1.56 | 34.44 \pm 2.32 | 36.60 \pm 1.80** | 10.320 | 0.0001 | 0.245 | 0.015 |
| Fibrinogen (mg/dL) | 362.22 \pm 21.72 | 369.82 \pm 22.65 | 378.54 \pm 17.09* | 7.836 | 0.001 | 0.160 | 0.091 |

KEY

N: Number of subjects in each group

P - value: P- value across all type 2 diabetics age groups

P value a vs b: P-value of comparison between the age group of 40-49 and 50-59 years in type 2 diabetics

P value b vs c: P-value of comparison between the age group of 50-59 and 60-69 years

*****: statistically significant when compared between the ages of 40-49 years ($P < 0.05$).

******: statistically significant when compared between the ages of 50-59 years ($P < 0.05$).

Table-2 shows the mean values of platelet count, and prothrombin time, activated partial thromboplastin time and fibrinogen in type 2 diabetics in relation to age.

There was progressive decrease in the mean value of platelet count across all age groups (231.44 \pm 18.44; 226.18 \pm 21.58; 222.42 \pm 17.23) which was not statistically significant ($P = 0.065$). When the value between the ages 50-59 years (226.18 \pm 21.58) was compared with the ages between 40-49 years (231.44 \pm 18.44), there was decrease which was not statistically significant ($p = 0.358$) and also there was decrease which was statistically significant ($p = 0.590$) when the value between 60 - 69 years (222.42 \pm 17.23) was compared with the ages between 50- 59 years (226.18 \pm 18.44).

There was no significant difference ($p = 0.892$) in the mean value of prothrombin time among all the age groups (13.60 \pm 1.31; 13.52 \pm 1.20; 13.28 \pm 1.23). There was no significant difference value between 40 - 49 years (13.60 \pm 1.31) and 50 -59 years (13.52 \pm 1.20) was not statistically significant ($p = 0.412$). Also, the mean value of ages between 60 - 69 years (13.28 \pm 1.23) with 50 - 59 years (13.52 \pm 1.20) was not statistically significant ($p = 0.602$).

Result showed that there was progressive increase in the mean value of activated partial thromboplastin time across all ages (33.56 \pm 1.56; 34.44 \pm 2.32; 36.56 \pm 1.80) which was statistically significant ($p = 0.001$). The mean value

between the ages of 50-59 years (34.44 \pm 2.32) was increased but was not statistically significant ($p = 0.245$) when compared with the mean value of ages between 40-49 years (33.56 \pm 1.56). The mean value between the ages of 60-69 years (34.44 \pm 2.32) was increased, but was not statistically significant ($p = 0.245$) when compared with the mean value of ages between 40-49 years (33.56 \pm 1.56). Also the mean value of ages between 60-69 years (36.56 \pm 1.80) was increased which was statistically significant ($p = 0.015$) when compared with the mean value of ages between 50-59 years (34.44 \pm 2.32).

There was a progressive increase in the mean value of fibrinogen across the ages (362.22 \pm 21.72; 369.82 \pm 22.65; 378.54 \pm 17.09) which was statistically significant ($p = 0.001$). the mean value between the ages of 50-59 years (369.82 \pm 22.65) was increased which was no statistically significant ($p = 0.160$ + when compared with the mean value of ages between 40-49 years (362.22 \pm 21.72). the mean value of ages between 60-69 years (378.54 \pm 17.09) was increased which was not statistically significant ($p = 0.091$ + when compared with the mean value of ages between 50-59 years (369.82 \pm 22.65).

DISCUSSION

In the study, higher level of platelet count was observed in type 2 diabetes when compared with the control subjects. Platelet hyperactivity occurs in type 2 diabetes when there was abnormal endothelial vascular dysfunction due to subclinical inflammation or cell wall injury which enhances vasoconstriction, increases release of cytokines and expression adhesion molecules such as intracellular cell adhesion molecules (ICAM) and vascular cell adhesion molecules (VCAM) which mediates platelets activation and adhesion to endothelium. This is in agreement with Soares *et al.*, [14] that reported that hyper platelet activation result in 2 to 3 times higher coronary artery disease risk in diabetics. This is in accordance with studies conducted by Akinsegun *et al.*, [15] that revealed higher mean platelet volume for diabetics. This agrees with the work of Alhadas *et al.*, [16] that reported positive correlation of platelet count with the fasting blood glucose. Kaur *et al.*, [7] observed high level of platelet as a result of endothelial and platelet hypersensitivity which may involve in endothelial dysfunction and vascular

disorders. Ferrein *et al.*, [17] observed that high level of platelet count result from increase platelet reactivity which was induced by non-glycation of membrane protein that decreased membrane fluidity and platelet adhesion. This is also in agreement with Alhadas *et al.*, [16], Pulani *et al.*, [18] who observed higher platelet count and suggested that long term complication of diabetes with marked platelet morphology could be associated with risk of developing vascular complication in diabetes contrary to present findings Buch *et al.*, [19], reported that platelet count was significantly decreased in diabetics due to increased platelet activity. In contrast in a cross-sectional studies conducted by Chen *et al.*, [20], there was no significant difference between platelet count and among diabetics when compared with non-diabetics. The study observed increase in various ages in type 2 diabetes which is not significant. This may be due to age related changes in platelet function in translocation platelets and unstable platelet interaction with von willie brand factor which result in increase adhesion to surface. This is in agreement by observational study conducted by Jones (2016). Also, Cowman reported that platelet function decreases in age due to decrease number of platelet tracking and interaction in von Williebrand factors. There was a slight increase in female type 2 diabetics which was not significant when compare with male diabetics. This may be due to reduction in oestrogen and deletion of oestrogen receptor in aged female which is expresses by platelet. This observation is supported by studies conducted Cowman *et al.*, [21]; Zhao *et al.*, [22].

The present study observed variation in blood coagulation. Lower level of prothrombin time was observed in type 2 diabetics when compared to control subjects. Prothrombin time is a screening test used to detect disorder involving contact with tissue factor which involve activation factor, ii, v, vii, ix, of extrinsic and common pathway. The shortened prothrombin time result from increased activation of hyperglycaemia induced glycation of coagulable protein ; prothrombin activation of coagulation factor which result in clot formation thrombosis increased pre-maline atherosclerotic plaque formation rupture occlusive thrombus and hypercoagulable state include endothelial dysfunction, coagulative activation, platelet hypersensitivity as a result of hyperglylaemia insulin resistance inflammation of oxidative stress. The coagulation detect contributes lot micro vascular and macro vascular complication such as diabetic nephropathy, retinopathy, neuropathy cardiovascular, cerebrovascular peripheral vascular disease. The finding of this study is consistent with previous studies. Karim *et al.*, [23] reported lower prothrombin time and concluded that type 2 diabetes were prone to develop coagulation defects. This is in concordance with the work of Ephram *et al.*, [24] that found the association shortened PT. with or without diabetes complication as

a coagulation risk factor in contrary to this study. Abdeen and Hamza *et al.*, [25] observed prolongation of PT due to deficiency of coagulation factors in relation to diabetic duration. Thukral *et al.*, [26] observed higher level of PTin type diabetics which indicated abnormal coagulation mechanism involving tendency of bleeding due to thromboembolic haemorrhagic disorder. A cross sectional study conducted by Obeagu *et al.*, [27] showed no significant difference in the level of prothrombin time between diabetics and control subjects. Abdulla *et al.*, [28] reported no significance in type 2 diabetics and control subjects. This study showed no significant difference in all age groups in type 2 diabetics. The findings are similar to the work of Ephraim *et al.*, [24]; Thukral *et al.*, [26] that reported no difference in age in PT level among diabetics. The findings of the study observed elevated level in female T2D which was not statistically significant. This may be due to increase in visceral obesity and hormonal changes such decrease in estrogen which may factor development of thrombosis. This agrees with the work of Ephraim *et al.*, [24] that found insignificant increase in female diabetics. In contrary, there was no significant difference in PT level between male and female type 2 diabetics which was reported by Elendo *et al.*, [29]; Abdulla *et al.*, [28].

The current study observed low level of activated partial thromboplastin time (APTT). This is a coagulation maker used in assessing abnormalities in intrinsic and common pathway, contact with prekallikren high molecular, Kinnogen ,fibrinogen , coagulation inhibitors and natural anticoagulant. The low level of APTT in diabetics is a risk of hypercoagulable state which enhances thromboembolic or occlusive thrombus within coronary or cerebral artery contributing to development of atherosclerotic lesion. This occurs due to hyperglycaemia glycation of intracellular and extracellular proteins which affect intrinsic clotting factors and triggers accumulation of these activated coagulation factor, delay action of coagulation inhibitors and fibinolytic system. The formation of uncontrolled thrombin is indicated by shortened APTT. The findings of this study are consistent with previous studies. Zhao *et al.*, [30] reported low level of APTT in type 2 diabetes which reflects pro coagulation imbalance with increase level of coagulation of factor. Mwambungu *et al.*, [31] reported low significant APTT in type 2 diabetes because T2DM patients are more prone to hyper coagulable state with increased thrombotic risk of cardiovascular events. This is in agreement with the work of Ankalayya *et al.*, [32] who reported shortened APTT in type 2 diabetes with thrombotic risks. Ambelu *et al.*, [33] reported low APTT level of 85% in untreated and 2.5% in treated type 2 diabetes. This agrees with the findings of Pan *et al.*, [34] that reported shortened APTT in T₂D was associated with diabetic complication such as

nephropathy. This is consistent with the study of Agarwal *et al.*, [32] that reported that low APTT occurred with or without diabetic complications. In contrary to this study, Alao *et al.*, [35] reported significant prolonged due to thrombo haemorrhage shift in haemostasis balance. This is supported by the work of Obeagu *et al.*, [27]; Abdeen and Hamza [25] found significant prolonged APTT level in type 2 diabetics as a result of inhibitors of intrinsic system and abnormal coagulation. Thurkral *et al.*, [26] reported elevated plasma level of APTT which occurs due to defect in intrinsic coagulation, no significance difference was observed in the level of APTT between T₂D and control subjects which was reported by Abdulla *et al.*, [28]. The finding on the study observed significant decrease in APTT level in diabetes as the ages progress, this indicates that coagulation defect increase the thrombotic risk as the ages increase. The findings is not in accordance with the study of Elendo *et al.*, [29]; Ephriam *et al.*, [24] reported no significant difference between various age groups in type 2 diabetics. This study observed no significant difference between male and female type 2 diabetics. This is consistent with the work of Abdulla *et al.*, [28] that reported no significant difference in type 2 diabetics in relation to sex. The findings to this study is inconsistent with work done by Elendo *et al.*, [29] that reported significant increase in female when compared to male type 2 diabetics.

Higher level of fibrinogen was observed in type 2 diabetes when compared with the control subjects. This is due to non enzymatic glycation of fibrinogen that promotes adhesion of endothelial receptors to platelet membrane, increases aggregation due to increase blood viscosity, reduction in tissue fibrinolysis from plasminogen to fibrinogen. Higher level of fibrinogen plays a role in formation of occlusive thrombosis over a rupture atherosclerotic plug in development of atherosclerosis in type diabetes. This implies that fibrinogen stimulates smooth cells proliferation and migration, increases coronary arterial diseases. The findings of this study agrees with the study of Bembale *et al.*, [36] that reported higher level of fibrinogen due to increased thrombotic tendency in diabetics. Grupta *et al.*, [37] also reported significant higher level of fibrinogen in diabetic with poor glycaemic control and its role in plaque formation in form of occlusive thrombus over ruptured atherogenesis. This is similar to the findings of Yang *et al.*, [38] that reported higher level of fibrinogen which is a marker of thromboembolism and inflammation that promotes ischemic stroke risk in diabetics. This is also consistent with the study by El-sayed *et al.*, (2018) reported higher fibrinogen level in type 2 diabetes due to changes in haemostatic mechanism that contributes to development of diabetic vascular diseases. There was progressive increase in fibrinogen level as the ages progress due to hepatic stimulation of fibrinogen which as associated with

inflammation, indicated a link between inflammation and hypercoagulation in advanced ages. This is in agreement with the work of Gupta *et al.*, [37]; Yang *et al.*, [38] that reported that plasma level of fibrinogen increases with ages. There was higher level of fibrinogen in female when compared with male type 2 diabetics. This is because fat content and hormonal difference in woman. This is not in agreement with the study conducted by Bembale *et al.*, [36] when reported insignificant higher level in female type 2 diabetics.

CONCLUSION

The findings of this study have shown that type 2 diabetics mellitus is associated with alteration in haemostatic system which is signified by platelet hyperactivity and hypercoagulable state. These undesirable state which play roles in the pathogenesis of type 2 diabetes may result in unexpected complications increased morbidity and premature death in type 2 diabetics.

REFERENCES

1. World Health Organization. (2016). Global reports on Diabetes. In World Health Organization Library.Meo design and communication. France. 1-84.
2. Fareed, M., Salam N., Khoja, A., & Abdulrahman, M. T. (2017). Life Style Related Risk Factor of Type 2 Diabetes Mellitus And Its Increased Prevalence in Saudi Arabia. *International Journal of Medical Research And Health Science*. 6(3): 125-132.
3. International Diabetes Federation. (2017). Diabetes Atlas. 8th Edition. 1-45.
4. Adeloye, D., Ige, J., Aderemi, A., Adeloye, V., Amoo, E., Auta, A., & Oni, G. (2017). Estimating the prevalence, Hospitalization and Mortality from Type 2, Diabetes Mellitus in Nigeria. *Biomedical Journal Open*.7 (5): 1-16.
5. Uloko, A., Musa, B., Ramalam M., Gezawa, I., Puepit F., Uloko, A. Borodo M., & Sada, K. (2018). Prevalence and Risk Factors for Diabetes Mellitus in Nigeria: A Systematic Review and Meta-Analysis. *Diabetes. Therapy*. 9(3):1307-1316.
6. Iloh, G., Chukwu, A., & Amadi, A. (2013). Burden of Non - Communicable Disease among Geriatric Nigeria in a Rural-Constrained. Setting of Eastern Nigeria. *Science Journal of Public Health*, 1:141-146.
7. Kaur R., Kaur M., & Singh J., (2018). Endothelial Dysfunction and Platelet Hyperactivity in Type 2 Diabetes Mellitus: Molecular Insights and Therapeutic Strategies. *Cardiovascular Diabetology*. 17:121.
8. Lemkes, B., Hermanides, J., Devries, J., Holleman, F., Meijers, J., & Hockstra, J. (2010). Hyperglycaemia, A protrombotic factor? *Journal of thrombosis and Haemostatis*. 8:1663-1669.

9. Holinstat, M. (2017). Normal Platelet Function. *Cancer Metastasis Review*. 36(2): 195-198.
10. Khalifa, J., & Abdul-Raheem, E. (2013). Haemostatic Profile in Saudi Patients with Type II Diabetes Mellitus. *International Journal of Health Sciences and Research*. 3(8):31-34.
11. Aronye, M. (2004). Size Determination In: Research Methodology with Statistics for Health and Social Sciences. 1st Edition, Nathadex Publishers. Illorin, 115-121.
12. Tietz, J. (2006). Boss Hog: The Dark Side of America's Top Pork Producer. *Rolling Stone*.
13. Lewis, M., Brain, B., & Bytes, I. (2006). Investigation of Haemostasis in: Dacie and Lewis Practical Haematology. 10th Edition. Church Hill Living Stone. United Kingdom. 379-440.
14. Soares, A., Sousa, M., Fernandes, A., & Carvalho, M. (2016). Hemostasis Changes in Patients with Type 2 Diabetes Mellitus. *Revista Brasileira De Haematologia Hemoterapia*. 32(6): 482-488.
15. Akinsegun, A., Olusola, D., Sara, J., Olajumoke, O., Adewumi .A, Majeed .O, Anthonia, O., Gbelle, U., Olaitan, O., Olanrewaju, A., & Kingsley, A. (2014). Mean Platelet Volume and Platelet Counts in Type 2 Diabetes Treatment and Non-diabetes Mellitus Controls in Lagos. *Pan African Journals*. 20(4):18.
16. Alhadas, K., Santos, S., Treitas, M., Viana, S., Ribeiro, L., & Costa, M. (2016). Are Platelets in Indices Useful in the Evaluation of Type 2 Diabetic Patients. *Journal Brasileiro de Patologia medicina laboratorial*. 52(2):96-102.
17. Ferrein, A. (2010). Robot controllers for highly dynamic environments with real-time constraints. *KI-Künstliche Intelligenz*, 24(2), 175-178.
18. Pulanić, D., Desnica, L., Perić, Z., Samardžić, A., Grce, M., Vrhovac, R., & Pavletić, S. Ž. (2018). Zagreb-center of chronic Graft-versus-Host Disease in November 2018.
19. Buch, A., Kaur, S., Nair, R., & Jain, A. (2017). Platelet Volume Indices as Predictive Biomarkers for Diabetic Patients *Journal of Laboratory Physicians*. 9(2):84-88.
20. Chen, X., Fang, L., Lin, H, Shen, P., Zhang, F., Li, H., Li, X., Yu, .M, Xu, C., Zhang, J., Lu, F., Du, X., Du, X., Hu, R., & Zhong, J. (2017). The Relationship between Type 2 Diabetes and Platelet Indicators. *Iranian Journal of Public Health*. 4(9):1211-1216.
21. Cowman, J., Dunne, E., Kenny, D. Ogelesby, I., Byrne, B. Ralph, A., Voison, B., Muller, S., & Riao, A. (2015). Age-Related Changes in Platelet Function are more Profound in Women than Men. *Scientific Reports*. 5:12235.
22. Zhao, F., Yan .Z., Meng, Z., Li, X., Ming,L., Ren, X., Zhu, M., He, Q., Zhang, Q., Song,K., Jia, O., Zhang, C., Wang, Liu, X., Zhang, X., Pan, Z., Liu, X. H., & Zhang, W. (2018). Relationship between Mean Platelet Volume and Metabolic Syndrome in Chinese Patients. *Scientific Report*. 8:14574.
23. Karim, F., Akter, S., Jahan, S., Khanom, A., Haque, S., Yeasmin, T., Siddika, T., & Sinha, S. (2015). Coagulation Impairment in Type 2 Diabetes mellitus *Journal of Bangladesh Society and Physiology*. 10(1): 26-29.
24. Ephraim, P., Awuka Y., Adu, P., Ampomah, L., Adoba, P., Abalzakey H., Panord, S., & Ninnoni, J. (2017). High risk of Coagulopathy among Type 2 diabetes mellitus client at a municipal Hospital in Ghana. *Ghana Medical Journal*. 3: 101-107.
25. Abdeen, H., & Hamza, K. (2013). Prothrombin Time PT and Activated Partial Thromboplastin Time (APTT) in Sudanese Diabetic Patients. *Journal of Natural and Medical Science*. 16 (1).
26. Thukral, S., Hussain, S., Bhar S., Kaur, N., & Reddy, A. (2018). Prothrombin Time (PT) and Activated Partied Thromboplastin Time (APTT) in Type 2 Diabetes Mellitus, A Case Control Study. *International Journal of Contemporary Medical Research* 5(8): H5-H8.
27. Obeagu I., Obarezi H., Aloh, S., & Emelike, U. (2014). Changes in Some Coagulation Parameters Among Diabetes Patients in Michael Okpara University Of Agriculture, Umudike Abia State Nigeria. *Journal of Pharmacy and Pharmaceutival Science*, 3(4):52-61.
28. Abdulla, A., Elmissabah, T., Hamid, E., A-Itom, F., & Abusham, M. (2017). Assessment and coagulation process in diabetes patients mellitus and Healthy individuals *International Journal of Contemporary Medical Research*. 3(11): 3170-3170.
29. Elendo, B., Nwoaga M., Okamgba, O., & Izuh, S. (2017). Assessment of Some Haemostatic Parameter among Diabetes Mellitus Patients In Bayelsa State: A Case Study at The Federal Medical Center, Yenugoa. *European Journal of Clinical and Biomedical Science*, 3(5):91-96.
30. Zhao, J., Jin, H., Gao, J., Pu, C., Zhang, P., Huang, J., Cheng, L., & Feng, G. (2018). Serum Extrantracellular Superoxide Dismutase is Associated with Diabetics Retinopathy Stage in Chinese Petients with Type 2 Diabetics Mellitus. *Disease Markers*, 8721379:1-9.
31. Mwabung, A., Kalie T., Korolova L., Kwenda J., & Marimo C. (2013). APTT A Screening Test for Hypercoagulability in Type 2 diabetes mellitus *Medical Journal of Zambia*, 40(3):112-118.
32. Agarwal, C., Bansal, K., Pujani, M., Singh, K., Chauhan, V., Rana, D., & Lukhmana, S. (2019). Association of coagulation profile with microvascular complications and glycemic control in type 2 diabetes mellitus-a study at a tertiary care center in Delhi. *Hematology, transfusion and cell therapy*, 41(1), 31-36.
33. Ambelu, G., Lovelock, B., & Tucker, H. (2018). Empty bowls: conceptualising the role of tourism

- in contributing to sustainable rural food security. *Journal of Sustainable Tourism*, 26(10), 1749-1765.
34. Tacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D. L., ... & Ouellette, M. (2018). Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. *The Lancet Infectious Diseases*, 18(3), 318-327.
35. Alao, O., Damulak, D., Joseph, D., & Puepet, F. (2009): Haemostatic profile of Patients with Type 2 Diabetes Mellitus in Northern Nigeria. *The Internet Journal of Endocrinology*. 6(1):1-7.
36. Bembde, A. (2012). A Study of Plasma Fibrinogen Level In Type 2 Diabetes Mellitus And Its Relation to Glycaemic Control. *International Journal of Haematology and Transfusion*. 28(2); 105-108.
37. Gupta, P., Bhambani P., & Narang, S. (2016). Study of Plasma Fibrinogen Level and Its Relation to Glycaemic Control in Type 2 Diabetes Mellitus Patients Attending Diabetes Clinic at a Tertiary Care Teaching Hospital in Madha Pradaesh India. *International Journal of Research in Medical Sciences*. 4(9) 3748-3754.
38. Yang, S., Du Y., Zhang, Y., Lin, X., Li, S. Xu, R., Zhu, C., Guo, Y., Wu, N., Qing, P., Gao, Y., Cui, C, Dong, Q., Sun, J., & Li, L. (2017) Serum Fibrinogen and Cardiovascular Events In Chinese Patients with Type 2 Diabetes And stable coronary Artery Disease. *BMJ Open*, 7(6):e015041.